LivaNova (NSDQ:LIVN) said today that it closed the $190 million sale of its cardiac rhythm management business to China’s MicroPort Scientific (HK:00853). The companies are already partners in a CRM join venture in the People’s Republic. LivaNova, formed by the $2.7 billion merger of Italy’s Sorin and Cyberonics in October 2015, said in September that it was putting the CRM business on the auction […]
Wall Street Beat
Aerie launches glaucoma drug in U.S.
Aerie Pharmaceuticals (NSDQ:AERI) today launched its once-daily eye-drop product, Rhopressa, which is designed to reduce intraocular pressure in patients with glaucoma or ocular hypertension. The Durham, N.C.-based company won FDA approval for Rhopressa in December last year, two months before the agency was expected to make a decision. Get the full story at our sister site, Drug Delivery […]
Boston Scientific closes $400m NxThera buy
Boston Scientific (NYSE:BSX) said today that it closed the $406 million acquisition of NxThera and its Rezūm benign prostatic hyperplasia device, which uses steam to ablate excess prostate tissue. The deal called for $306 million in up-front cash from Marlborough, Mass.-based Boston Scientific, with another $100 million in potential milestones over the next four years. Boston, which in December 2015 led […]
United Therapeutics puts $216m on the table to buy rival SteadyMed
United Therapeutics (NSDQ:UTHR) today signed a deal to acquire competitor SteadyMed (NSDQ:STDY) for $4.46 per share in cash at closing and $2.63 per share in cash if the combined company can win approval for SteadyMed’s Trevyent drug-device combination therapy. The merger, valued at $216 million, combines two companies that were in court as recently as last November, fighting […]
Sales for Tandem Diabetes Care climb 44% in Q1
Shares in Tandem Diabetes Care (NSDQ:TNDM) fell -3% today after the insulin pump maker topped revenue expectations, but missed earnings estimates on Wall Street with its first-quarter results. The San Diego, Calif.-based company posted a net loss of -$32.7 million, or -$1.82 per share, on sales of $27.3 million for the 3 months ended March 31, for […]
Flexion touts interim data from Ph3 trial of osteoarthritis injection
Flexion Therapeutics (NSDQ:FLXN) this week touted updated, interim results from an ongoing Phase IIIb study evaluating the safety and tolerability of repeat administration of its osteoarthritis injection, Zilretta. The company’s injectable suspension is an extended-release formulation of triamcinolone acetonide designed for patients with osteoarthritis of the knee. Top-line results from Flexion’s trial showed that 95% of […]
ResMed posts Street-beating Q3
Shares in ResMed (NYSE:RMD) have fallen today despite the respiratory device maker beating expectations on Wall Street with its fiscal year 2018 third quarter earnings release. The San Diego, Calif.-based company posted profits of $110.1 million, or 76¢ per share, on sales of $591.6 million for the three months ended March 31, for bottom-line growth of […]
AtriCure jumps on Q1 profit increase
Shares in AtriCure (NSDQ:ATRC) got a boost today after the cardiovascular company’s first-quarter numbers showed a nearly 14% top-line gain and shaved a penny off its quarterly earnings loss. Mason, Ohio-based AtriCure posted losses of -$10.1 million, or -31¢ per share, on sales of $47.0 million for the three months ended March 31, cutting its losses […]
Stryker Q1 beats The Street
Shares in Stryker (NYSE:SYK) have fallen slightly today after the medical device maker posted first quarter earnings that topped Wall Street expectations but saw sales shrink slightly. The Kalamazoo, Mich.-based company posted profits of $443 million, or $1.16 per share on sales of $3.2 billion for the three months ended March 31, seeing the bottom-line shrink […]
Profits slide for Hill-Rom as it names Bard vet Groetelaars CEO
Hill-Rom Holdings (NYSE:HRC) said today that it’s naming C.R. Bard veteran John Groetelaars to be its new chief executive, effective May 14, as it reported a fiscal second-quarter profit slide on results that still managed to top the consensus. Groetelaars is succeeding John Greisch, who in January announced his plans to retire by the fiscal third quarter. His […]
Sanofi misses estimates in Q1, announces $1.5B share buyback
Sanofi (NYSE:SNY) shares fell -3% today after the company posted its first-quarter results, missing estimates on Wall Street and revealing plans for a $1.5 billion share buyback program. The Paris, France-based company saw sales decline -8.7% in the first three months of the fiscal year compared to 2017, landing at $9.55 billion for the quarter. Analysts […]